Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › cetuximab

cetuximab

15 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of cetuximab

178 trials tracked of cetuximab: 25 in phase 3 or 4 and 16 with published results. The most-cited published study has 3076 citations.

178Trials tracked
25Phase 3 & 4
0Recruiting
16With published results
Phase distribution
Phase 3 25 Phase 2 144 Phase 1 5 Other / NA 4
  1. Phase 3 Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) Completed · 3,076 cited
  2. Phase 3 Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040) Completed · 1,723 cited
  3. Phase 3 Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer Completed · 1,313 cited
  4. Phase 3 Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer Completed · 837 cited
  5. Phase 3 Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) Completed · 812 cited
  6. Phase 3 High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Completed · 590 cited
Show 44 more trials
  1. Phase 3 Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer Completed · 562 cited
  2. Phase 3 A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) Completed · 512 cited
  3. Phase 3 A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients Completed · 260 cited
  4. Phase 3 Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer Completed · 213 cited
  5. Phase 3 S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer Completed · 66 cited
  6. Phase 3 Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Completed · 66 cited
  7. Phase 3 Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer Completed · 63 cited
  8. Phase 3 Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin Completed · 61 cited
  9. Phase 3 Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) Completed · 18 cited
  10. Phase 3 Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer Completed · 18 cited
  11. Phase 3 Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer Completed
  12. Phase 3 Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Completed
  13. Phase 3 ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer Completed
  14. Phase 3 Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer Completed
  15. Phase 3 Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer Completed
  16. Phase 3 Erbitux in Combination With Xeloda and Cisplatin in Advanced Esophago-gastric Cancer Completed
  17. Phase 3 Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer Completed
  18. Phase 3 Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL) Completed
  19. Phase 3 A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck Completed
  20. Phase 2 Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck Completed
  21. Phase 2 MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab Completed
  22. Phase 2 Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy Completed
  23. Phase 2 Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer Completed
  24. Phase 2 Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck Completed
  25. Phase 2 Study of Cetuximab With and Without Weekly Paclitaxel for Patients With Previously Treated Advanced Urothelial Cancer Completed
  26. Phase 2 Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery Completed
  27. Phase 2 Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer Completed
  28. Phase 2 EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer Completed
  29. Phase 2 Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors Completed
  30. Phase 2 Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer Completed
  31. Phase 2 Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer Completed
  32. Phase 2 Study to Evaluate the Effect of Cetuximab on Corrected QT (QTc) Interval Changes in Patients With Advanced Malignancies From Solid Tumors Completed
  33. Phase 2 Cetuximab and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer Completed
  34. Phase 2 A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203) Completed
  35. Phase 2 Palbociclib and Cetuximab in Metastatic Colorectal Cancer Completed
  36. Phase 2 A Phase II Trial of Cetuximab and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer Completed
  37. Phase 2 Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer Completed
  38. Phase 2 A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer Completed
  39. Phase 2 Induction Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck Completed
  40. Phase 2 A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer Completed
  41. Phase 2 Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer Completed
  42. Phase 2 A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before Completed
  43. Phase 2 Preoperative Treatment With Cetuximab and/or IMC-A12 Completed
  44. Phase 2 Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed

Showing the 50 most-cited and recently-updated of 178 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
IMRT plus cetuximab does not improve quality of life compared to IMRT plus cisplatin
ENT (Otolaryngology) RCT
IMRT plus cetuximab does not improve quality of life compared to IMRT plus cisplatin Trial compares cetuximab and cisplatin for oropharyngeal cancer quality of life
This Phase III randomized controlled trial of 375 patients with p16+ oropharyngeal cancer found no significant difference in quality of life…
A clinical trial found that replacing cisplatin with cetuximab did not improve quality of life or swallowing for patients with oropharyngeal…
Sep 12, 2026
Cetuximab-based regimens achieve 47% objective response rate in HNSCC after immune checkpoint inhibitor failure
ENT (Otolaryngology) Meta-analysis
Cetuximab-based regimens achieve 47% objective response rate in HNSCC after immune checkpoint inhibitor failure Cetuximab shows activity for head and neck cancer patients
This meta-analysis evaluates cetuximab-based regimens for patients with recurrent or metastatic head and neck squamous cell carcinoma follow…
New data shows cetuximab-based treatments provide meaningful results for head and neck cancer patients after other treatments fail.
Sep 8, 2026
PD-1/PD-L1 inhibitors provide superior overall survival compared to chemotherapy or cetuximab in platinum-refractory HNSCC
Drug Pipeline Meta-analysis
PD-1/PD-L1 inhibitors provide superior overall survival compared to chemotherapy or cetuximab in platinum-refractory HNSCC Newer drugs show better survival for advanced head and neck cancer
This meta-analysis of 5 RCTs involving 1,700 patients found that PD-1/PD-L1 inhibitors resulted in superior overall survival (HR: 0.80) comp…
A review of clinical trials shows that certain immunotherapy drugs offer better survival rates and fewer severe side effects than traditiona…
Frontiers Aug 24, 2026
Dabrafenib and trametinib produce rapid response in a single case of BRAF V600E-mutant PHC
Oncology Sys. Review
Dabrafenib and trametinib produce rapid response in a single case of BRAF V600E-mutant PHC Targeted Treatment Shows Promise for Rare Pancreatic Cancer Type
This systematic review and case report analyze pancreatic hepatoid carcinoma (PHC) and the role of targeted therapies. The analysis identifi…
A specific drug combination showed a rapid and deep response in a patient with a rare type of pancreatic cancer involving a BRAF mutation.
Frontiers Aug 19, 2026
Alpha-gal syndrome review: delayed reactions, 15,000 new US cases yearly
Allergy & Immunology Sys. Review
Alpha-gal syndrome review: delayed reactions, 15,000 new US cases yearly Tick Bite Allergy: 15,000 New Cases Each Year
This mini-review summarizes alpha-gal syndrome (AGS), an IgE-mediated sensitivity to galactose-alpha-1,3-galactose, typically causing delaye…
A tick bite can trigger a delayed meat allergy. New cases in the US are estimated at 15,000 yearly.
Frontiers Aug 17, 2026
Molecular drivers including DNA damage response and epigenetics contribute to treatment resistance in HPV-positive OPSCC
Genetics & Precision Medicine Sys. Review
Molecular drivers including DNA damage response and epigenetics contribute to treatment resistance in HPV-positive OPSCC Understanding the Molecular Causes of Treatment Resistance in Throat Cancer
This systematic review examines the molecular architecture of treatment resistance in patients with HPV-positive oropharyngeal squamous cell…
Doctors are looking into why some throat cancers do not respond to standard treatments like radiation and chemotherapy.
Frontiers Aug 7, 2026
Lenvatinib plus pembrolizumab did not improve overall survival compared to standard of care
Oncology RCT
Lenvatinib plus pembrolizumab did not improve overall survival compared to standard of care Trial shows lenvatinib and pembrolizumab do not improve survival
This Phase 2 randomized trial evaluated lenvatinib and pembrolizumab in 374 adults with recurrent or metastatic head and neck squamous cell …
A Phase 2 trial found that a combination of lenvatinib and pembrolizumab did not improve overall survival for patients with advanced head an…
Jul 27, 2026
EGFR inhibitors show reproducible activity and manageable toxicity in locally advanced or metastatic anal squamous cell carcinoma
Oncology Meta-analysis
EGFR inhibitors show reproducible activity and manageable toxicity in locally advanced or metastatic anal squamous cell carcinoma EGFR Inhibitors Show Activity in Advanced Anal Squamous Cell Carcinoma
This meta-analysis of 404 patients evaluated EGFR inhibitors (cetuximab and panitumumab) for anal squamous cell carcinoma. The analysis foun…
New analysis shows that EGFR inhibitors like cetuximab and panitumumab may improve response rates for patients with advanced anal squamous c…
Jul 5, 2026
Cetuximab maintenance therapy prolongs progression-free survival and overall survival versus observation in metastatic colorectal cancer
Drug Pipeline Meta-analysis
Cetuximab maintenance therapy prolongs progression-free survival and overall survival versus observation in metastatic colorectal cancer Cetuximab maintenance therapy extends survival in metastatic colorectal cancer
This systematic review and meta-analysis evaluated cetuximab maintenance therapy versus observation in metastatic colorectal cancer patients…
A new analysis finds that continuing cetuximab after initial treatment may help people with metastatic colorectal cancer live longer without…
Frontiers Jun 3, 2026
Avelumab plus cetuximab versus cetuximab alone in metastatic colorectal cancer patients
Gastroenterology RCT
Avelumab plus cetuximab versus cetuximab alone in metastatic colorectal cancer patients Adding avelumab to cetuximab helps only a specific subgroup of colorectal cancer patients
This randomized phase II trial evaluated adding avelumab to cetuximab in RAS/BRAF wild-type metastatic colorectal cancer patients.
A new trial shows adding avelumab to cetuximab improves survival only for patients without certain genetic changes, not for everyone.
May 1, 2026
Sequential cetuximab-bevacizumab vs bevacizumab-EGFR mAb shows no DDC difference in metastatic CRC
Oncology RCT
Sequential cetuximab-bevacizumab vs bevacizumab-EGFR mAb shows no DDC difference in metastatic CRC New Drug Order Doesn't Beat Old Standard
A phase III randomized controlled trial in 263 untreated, unresectable wild-type RAS/BRAF metastatic colorectal cancer patients found no dif…
A new drug order for advanced colon cancer did not improve disease control or survival compared to the standard treatment sequence.
Apr 16, 2026
Case report suggests grade 3 ICI-induced inflammatory arthritis may correlate with sustained response to tislelizumab in advanced head and neck carcinoma
Rheumatology Cohort
Case report suggests grade 3 ICI-induced inflammatory arthritis may correlate with sustained response to tislelizumab in advanced head and neck carcinoma Could a painful joint flare actually signal that cancer treatment is working long-term?
This case report and literature review describes a single patient with advanced unknown primary carcinoma of the head and neck receiving mai…
A patient with advanced head and neck cancer stayed in complete remission for over a year after joint pain from treatment forced doctors to …
Frontiers Apr 14, 2026

All cetuximab Articles